Dublin, April 12, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Therapeutic Drug Monitoring - Technologies, Markets, and Companies" to their offering.
This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome. TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse (DoA). Various technologies used for well-known DoA are described.
A section on drug abuse describes methods of detection of performance-enhancing drugs. TDM market is analyzed from 2015 to 2025 according to technologies as well as geographical distribution. Global market for DoA testing was also analyzed from 2015 to 2025 and divided according to the area of application. Unmet needs and strategies for development of markets for TDM are discussed.
The report contains profiles of 27 companies involved in developing tests and equipment for drug monitoring along with their collaborations. The text is supplemented with 18 tables, 6 figures and 190 selected references from literature.
Who should read this report?
- Biotechnology companies developing assays and equipment for drug monitoring.
- Reference laboratories providing drug monitoring services.
- Pharmaceutical companies interested in companion tests for monitoring their drugs.
- Clinical pharmacologists interested in integrating therapeutic drug monitoring with pharmacogenetics for development of personalized medicine.
Key Topics Covered:
Executive Summary
1. Introduction
2. Technologies for TDM
3. Drug Monitoring Instruments
4. Applications of TDM
5. Drugs Requiring Monitoring
6. Monitoring of Biological Therapies
7. Monitoring of Drug Abuse
8. Markets for TDM
9. Companies
10. References
For more information visit http://www.researchandmarkets.com/research/d48q5h/therapeutic_drug
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Drug Discovery


AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Italy Fines Apple €98.6 Million Over App Store Dominance
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 



